

VibeDx™



Diagnostic Corp.

A patent-pending medical device for spine diagnosis.

80% of all people
have back problems

90% of problems
can't be diagnosed














\$86 billion/yr on
back problems in USA

MRIs not the answer
~50% unnecessary

Questionable value
for back patients
Emery, JAMA






A cheaper, better, faster diagnostic
alternative is needed for back problems




VibeDx[™] Technology

The logo graphic for VibeDx consists of a series of overlapping, wavy lines in shades of orange and yellow, creating a sense of motion or vibration. These lines are positioned below the 'VibeDx' text and extend horizontally across the width of the 'VibeDx' portion of the logo.


Diagnostic Corp.












L14-5

VibeDx[™] Evolution

Diagnostic Corp.

Prototype 1

- Invasive technology
- 15 unique cadaveric injuries
- In 5040 trials, technology was correct 5030 times (>99% diagnostic accuracy)





Cameron Schuler – CEO

- 5 start-ups
- Structured partnership with EU company for cancer therapy
- Partnership with top 10 health authority
- Raised >\$45 million in the U.S. and Canada



Dr. Greg Kawchuk – Inventor, CSO

- Canada Research Chair Spinal Function
- 15 years of clinical practice
- Associate Professor, University of Alberta




Dr. Anthony Au – Research Engineer

- Ph.D. & Post-Doctoral Fellow in spine modeling and testing

Prototype 2 - Denmark

- 10 twin sets
- 5 similar / 5 dissimilar
- VibeDx correctly identified twins as similar or not
- Pathologies included:
 - Disc herniation
 - Disc degeneration
 - Hemangioma
 - Fusion
 - Compression fracture





Company History

- Company founded 2010
- TEC VenturePrize 2011
- >\$600,000 invested to date





Prototype 3 - HealthPointe

- High throughput spine clinic
- Clinical trial 1/3 complete
- Purpose:
 - Build clinical value proposition






Business Plan



Stage of commercialization





USA Market

- 8,800 MRIs
- 18,500 Institutions
- 220k MD offices
- 100k DC offices



Pull strategy


- Clinical influencers
 - Orthopaedic surgeons, physiatrists, GPs, radiologists, chiropractors, physical therapists, occupational therapists, veterinarians
- Legal & Insurance
- Patients
 - Improved information
 - Improved care pathway
 - Patient satisfaction





Push strategy

- Sales Strategy
- Sales & Marketing Partnership
 - Relationships with the right customers
 - Established distribution channels
 - Accretive sales for partner



Revenue Drivers

- Devices
 - 78%
- Training
 - 9%
- Service Agreements
 - 8% recurrent
- Consumables
 - 5% recurrent





Financials


- COGS <55%
- 5-year target
 - 200 units
 - <1% of market
 - ~18x return for investors
 - (Morningstar Research Medical Device Valuation 5X of Revenue)





Summary

- Multi-billion dollar market
- No special resources
- Cost < 10% of MRI
- Patient throughput ↑ 4-6X
- 18 month ROI/payback





VibeDx Diagnostic Corp.
Suite 4224, 10230 Jasper Avenue NW
Edmonton, Alberta, Canada T5J 4P6

Cameron Schuler, Co-founder, President & CEO
cameron@vibedx.com
+1.780.238.6740

Greg Kawchuk, Co-founder & Chief Scientific Officer
greg@vibedx.com
+1.780.965.6891

www.vibedx.com

VibeDx™



Diagnostic Corp.

A patent-pending medical device for spine diagnosis.

This forward looking information as to revenue and EBIT is subject to certain risks including the inability of the company to acquire additional customers, the inability to access capital, the default of contractual obligations by third parties, the loss of key management, fluctuations in currency exchange rates, changes in the protocols in which current print drivers are based on and changes in legislation that affects the software or print industry. As a result of these risks, actual revenue and EBIT may vary which variation could differ materially from the forward looking information above. The forward looking information contained in this document is made as of the date hereof and excepting for updating forward looking information as required by Canadian securities law including the Management Discussion and Analysis, VibeDx Diagnostic Corp. do not undertake any obligation to update publicly or to revise any of the above forward looking information. The forward looking information contained herein is expressly qualified by this cautionary statement.

Financing

- Pre-money valuation \$2,250,000 @ >90% discount rate
- Financing: \$1,000,000 common shares \$0.15
- Invested to date: >\$600K
- Future financings:
 - 20 months \$2,500,000
- 4-6 year exit





Use of funds

- Product development
- Initial regulatory & reimbursement
- Market development
 - Build partner relationships
 - Build practitioner networks

	Oct/13 - Sep/14	Oct /14-Jun/15
Regulatory & Reimbursement		
Preclinical & Clinical Trials		
Product Development		
Build Practitioner Network		
Industrial Partnership		
Cultivate Follow-on Investors		